VAXESS

April 10, 2020

MIMIX COVID-19: The Only Single-Dose, Shelf-Stable, Self-Applied SARS-CoV-2 Vaccine

Vaxess

The Only Single-Dose, Shelf-Stable, Self-Applied SARS-CoV-2 Vaccine

The Challenge
Need to rapidly scale SARS-CoV-2 vaccine globally
Over 41 SARS-CoV-2 Vaccines are Under Development Best case scenario, 18 months to launch
Moderna vaccine requires two injections 28 days apart
Traditional vaccine delivery risks cross-infection as hospitals are a primary source of COVID19.

[Reading the full article here ]